Trial Profile

A Phase II Study to Evaluate the Efficacy and Safety of Selinexor in Patients With Myelofibrosis Refractory or Intolerant to JAK1/2 Inhibitors

Status: Active, no longer recruiting

Phase of Trial: Phase II

Latest Information Update: 11 Apr 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Selinexor (Primary)
Indications Myelofibrosis
Focus Therapeutic Use
Acronyms ESSENTIAL

Most Recent Events

08 Apr 2025 Planned End Date changed from 14 Mar 2025 to 1 May 2025.
18 Mar 2024 Status changed from recruiting to active, no longer recruiting.
08 Feb 2022 According to a Karyopharm Therapeutics media release, data presented at the upcoming American Society of Hematology (ASH) 2021 Annual Meeting and Exposition.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com